On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
FridayJun 11, 2021 9:15 am

FingerMotion Inc. (FNGR) Releases FY 2021 Results, Showing Impressive Year-Over-Year Growth and Substantial Positive Shareholders’ Equity

FingerMotion Inc. reported total annual revenue of $16.68 million for the 2021 financial year ended February 28, 2021 This FYE 2021 results represented an 82% growth from the FYE 2020 results The company also posted $2.11 million in positive shareholders’ equity The growth was attributed to an increase in subscriber numbers, resource optimization, and the mix between Top-up and SMS product and service offerings Founded in 2016 as a mobile gaming enterprise, FingerMotion (OTCQX: FNGR) has become a leading mobile services and data company. In the 2021 financial year, FingerMotion, Inc posted its highest revenue and year-over-year revenue growth thus…

Continue Reading

FridayJun 11, 2021 9:15 am

Q1 Production’s 7th Annual Global Regulatory Affairs CMC Conference Designed to Maximize Learning and Engagement

Date: June 15-17, 2021Virtual EventEvent Highlights The conference aims to ensure compliant pre-market and post-market operations  The event will feature case studies, panel discussions, and presentations by 15+ industry professionals holding senior positions at various pharmaceutical and biotechnology companies Attendees should expect to get their unique needs addressed as the program includes Q&A sessions after every discussion There will be 30-minute virtual networking sessions daily As an organizer whose mission is to propel highly regulated industries forward through platforms of curated executive learning with a focus on quality, Q1 Productions invites you to one such platform: the 7th Annual Global…

Continue Reading

FridayJun 11, 2021 9:15 am

Hero Technologies Inc. (HENC) Establishes Strong Position, Portfolio in Growing Market

Marijuana sales in Michigan hit record $115.4 million in March, more than twofold increase over March 2020 U.S. marijuana markets forecasted to reach an estimated $45.9 billion in annual sales by 2025 HENC focused on developing “largest vertically integrated cannabis company the world has ever known” The numbers being reported in Michigan’s cannabis space are impressive, and companies operating in the state, such as Hero Technologies (OTC: HENC), are watching the growth of the industry closely. The state’s numbers should only increase as the cannabis market in the United States hits record highs.  “Recreational and medical marijuana sales in the state…

Continue Reading

FridayJun 11, 2021 9:00 am

Cybin Inc. (NEO: CYBN) (OTCQB: CLXPF) to Sponsor Kernel Flow, Ketamine Feasibility Study

Feasibility study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics Cybin, Kernel working together to leverage proprietary Kernel Flow device for psychedelic-based studies and clinical trials Ketamine is a dissociative injected anesthetic that blocks sensory perception Cybin (NEO: CYBN) (OTCQB: CLXPF) has announced a key step forward in its focus on progressing psychedelic therapeutics. The company will be sponsoring a feasibility study of the Kernel Flow technology; the study is designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/BW1Jn).  “We still have much to learn about what is occurring in the brain during a psychedelic…

Continue Reading

FridayJun 11, 2021 9:00 am

Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF) on Course for Private Demonstrations of the i/Blue Imaging System(TM) at the American Urological Association Annual Conference in September

Further refinement of if the i/Blue Imaging System will incorporate changes intended to meet critical verification requirements established through benchmark testing of competitive systems as well as feedback from preliminary meetings with the FDA Bladder cancer is anticipated to cause over 1,000,000 physician consultations per year, resulting in $4 billion in total costs for bladder cancer treatment and management Imagin Medical plans to complete its proprietary i/Blue Imaging System in 2022 The National Cancer Institute (“NCI”) lists urinary bladder cancer as the sixth most prevalent form of cancer in the United States. In 2021, NCI estimates that the total number…

Continue Reading

FridayJun 11, 2021 9:00 am

HempFusion Wellness Inc. (TSX: CBD.U) (OTC: CBDHF) (FWB: 8OO) Celebrates Revival of High-volume UAE Sales, Retail Expansion Through Proposed Apothecanna Acquisition

Health and wellness CBD-based probiotics distributor HempFusion Wellness, Inc. recently announced an agreement to acquire CBD brand pioneer Apothecanna’s holding company The deal will give HempFusion an additional 1,800 retail outlets for its brand, notably in CVS stores, to supplement the 4,000 retail locations HempFusion already uses in all 50 states Apothecanna’s sales revenues during 2020 were more than $4 million — double HempFusion’s historical revenue HempFusion also recently announced that a multi-billion-dollar customer in Dubai, United Arab Emirates, has revived its product purchases after more than a year’s pause in international sales during the pandemic Health and wellness supplement…

Continue Reading

ThursdayJun 10, 2021 10:43 am

Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) to Present at H.C. Wainwright’s Upcoming Virtual Psychedelics Conference

Tryp Therapeutics’ Chairman and CEO Greg McKee will present at the virtual Psychedelics in Psychiatry and Beyond Conference planned for Thursday, June 17, 2021 As part of his presentation, McKee will discuss Tryp’s business and its pipeline, which includes its proprietary psilocybin-centered drug development program Tryp will present alongside other pharmaceutical companies leading research in psychedelic-assisted therapeutics Psychedelics have increasingly drawn the attention of different players and companies thanks to the research-driven revelations regarding their utility in treating a wide range of neuropsychiatric diseases.  As a pharmaceutical company that has been furthering such research – specifically on psilocybin, a psychedelic…

Continue Reading

ThursdayJun 10, 2021 10:29 am

Chalice Brands Ltd. (CSE: CHAL) (OTCQB: CHALF) Earns BUY Rating, Coverage from Fundamental Research Corp

New report cites new management, very good customer ratings and record revenue in initiating CHAL coverage Chalice Brands acquisition of Homegrown Oregon also noted CHAL’s consistent increase in financial numbers key to BUY rating as well A recent Fundamental Research Corp. report has initiated coverage of Chalice Brands (CSE: CHAL) (OTCQB: CHALF) with a BUY rating and a fair value estimate of C$2.46 (https://ibn.fm/W7HfD). CHAL closed at C$1.37 on June 8, 2021.  Chalice is a leader in retail, marketing and craft cultivation supported by fully integrated processing and distribution. “New management has demonstrated their ability by significantly growing the company’s revenue…

Continue Reading

ThursdayJun 10, 2021 10:04 am

United Medical Equipment Business Solutions Network Inc. May Offer Response to US Prescription Drugs Price Crisis; Provides GoodRx Functionality within its Medication Management App

Americans pay more for prescription drugs than any other nation in the world; prices keep increasing Patients pay about 14% of prescription drug costs out of pockets; around 20% report not being able to complete a prescribed course of medicine due to costs UME's committed to providing consumers better access to the healthcare they need; its Medication Management App features GoodRx in-built functionality enabling them to view discount prices and coupons United Medical Equipment Business Solutions Network ("UME") has developed the Medication Management App with twelve different functionalities within the convenience of one application, with the newest addition of GoodRX…

Continue Reading

ThursdayJun 10, 2021 9:50 am

Brain Scientific Inc. (BRSF) Poised to Offer Brain Monitoring Solution as Research Shows Neurological Findings in COVID-19 Long-Haulers

Most extensive research to date reports significant neurological problems in patients who suffered from so-called long-haul COVID-19 Neurological issues range from mild to more severe such as cognitive impairment, which affects around 20% of these patients BRSF appears poised to be part of the solution as long-haulers need monitoring so that doctors can assess if they have neurological disorders The neurological and psychiatric aftermath of COVID-19 has been reported, but adequately assessing the effects of the disease on brain health still remains a challenge. A new preprint analysis, representing one of the most extensive studies of neuropsychiatric symptoms among COVID-19…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered